niacinamide has been researched along with Weight Gain in 19 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Weight Gain: Increase in BODY WEIGHT over existing weight.
Excerpt | Relevance | Reference |
---|---|---|
"We investigated the change of tryptophan-niacin metabolism in rats with puromycin aminonucleoside PAN-induced nephrosis, the mechanisms responsible for their change of urinary excretion of nicotinamide and its metabolites, and the role of the kidney in tryptophan-niacin conversion." | 7.73 | Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis. ( Egashira, Y; Nagaki, S; Sanada, H, 2006) |
"Ecological evidence suggests that niacin (nicotinamide and nicotinic acid) fortification may be involved in the increased prevalence of obesity and type 2 diabetes, both of which are associated with insulin resistance and epigenetic changes." | 3.79 | Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. ( Cao, JM; Cao, Y; Gong, XJ; Guo, J; Guo, M; Li, D; Lun, YZ; Luo, N; Sun, WP; Tian, YJ; Zhou, SS, 2013) |
"We investigated the change of tryptophan-niacin metabolism in rats with puromycin aminonucleoside PAN-induced nephrosis, the mechanisms responsible for their change of urinary excretion of nicotinamide and its metabolites, and the role of the kidney in tryptophan-niacin conversion." | 3.73 | Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis. ( Egashira, Y; Nagaki, S; Sanada, H, 2006) |
" In the presence of excess dietary nicotinamide, chicks fed the corn-casein diet achieved maximal weight gain when 100 mg/kg of L-tryptophan was supplemented." | 3.68 | Quantitative efficacy of niacin sources for chicks: nicotinic acid, nicotinamide, NAD and tryptophan. ( Baker, DH; Oduho, GW, 1993) |
" As the result, the urinary excretion of Nam, N1-methyl-4-pyridone-3-carboxamide (4-Py), Nam + N1-methylnicotinamide (MNA) + N1-methyl-2-pyridone-5-carboxamide (2-Py) + 4-Py was lower in the CCl4-treated groups than in the non-treated group (control) regardless of the experimental period (1 mo and 2 mo) or dosing amount of CCl4 (0." | 1.30 | Tryptophan-niacin metabolism in liver cirrhosis rat caused by carbon tetrachloride. ( Egashira, Y; Isagawa, A; Komine, T; Ohta, T; Sanada, H; Shibata, K; Yamada, E, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (31.58) | 18.2507 |
2000's | 8 (42.11) | 29.6817 |
2010's | 4 (21.05) | 24.3611 |
2020's | 1 (5.26) | 2.80 |
Authors | Studies |
---|---|
Méndez-Lara, KA | 1 |
Rodríguez-Millán, E | 1 |
Sebastián, D | 1 |
Blanco-Soto, R | 1 |
Camacho, M | 1 |
Nan, MN | 1 |
Diarte-Añazco, EMG | 1 |
Mato, E | 1 |
Lope-Piedrafita, S | 1 |
Roglans, N | 1 |
Laguna, JC | 1 |
Alonso, N | 1 |
Mauricio, D | 1 |
Zorzano, A | 1 |
Villarroya, F | 1 |
Villena, JA | 1 |
Blanco-Vaca, F | 1 |
Julve, J | 1 |
Li, D | 1 |
Tian, YJ | 1 |
Guo, J | 1 |
Sun, WP | 1 |
Lun, YZ | 1 |
Guo, M | 1 |
Luo, N | 1 |
Cao, Y | 1 |
Cao, JM | 1 |
Gong, XJ | 1 |
Zhou, SS | 1 |
Ying, HZ | 1 |
Zang, JN | 1 |
Deng, LL | 1 |
Wang, ZY | 1 |
Yu, CH | 1 |
Shibata, K | 8 |
Imai, S | 1 |
Nakata, C | 1 |
Fukuwatari, T | 3 |
Cantó, C | 1 |
Houtkooper, RH | 1 |
Pirinen, E | 1 |
Youn, DY | 1 |
Oosterveer, MH | 1 |
Cen, Y | 1 |
Fernandez-Marcos, PJ | 1 |
Yamamoto, H | 1 |
Andreux, PA | 1 |
Cettour-Rose, P | 1 |
Gademann, K | 1 |
Rinsch, C | 1 |
Schoonjans, K | 1 |
Sauve, AA | 1 |
Auwerx, J | 1 |
Wada, H | 1 |
Sasaki, R | 2 |
Lo, HC | 1 |
Tu, ST | 1 |
Lin, KC | 1 |
Lin, SC | 1 |
Takahashi, C | 1 |
Egashira, Y | 2 |
Nagaki, S | 1 |
Sanada, H | 2 |
Nakamura, T | 1 |
Terajima, T | 1 |
Ogata, T | 1 |
Ueno, K | 1 |
Hashimoto, N | 1 |
Ono, K | 1 |
Yano, S | 1 |
Goestemeyer, AK | 1 |
Marks, J | 1 |
Srai, SK | 1 |
Debnam, ES | 1 |
Unwin, RJ | 1 |
Oduho, GW | 1 |
Baker, DH | 1 |
Mushiage, M | 1 |
Kondo, T | 3 |
Hayakawa, T | 1 |
Tsuge, H | 1 |
Shimada, H | 2 |
Taguchi, H | 1 |
Marugami, M | 1 |
Umezawa, C | 1 |
Isagawa, A | 1 |
Komine, T | 1 |
Yamada, E | 1 |
Ohta, T | 1 |
Mokudai, T | 1 |
Ayoub, IA | 2 |
Sakakibara, Y | 1 |
Lee, EJ | 1 |
Ogilvy, CS | 1 |
Maynard, KI | 2 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Validation of an Enzymatic Assay for Quantification of Nicotinamide Adenine Dinucleotide in Blood Plasma After Ingestion of the Vitamin B3 Variant Nicotinamide Riboside: a Randomized Controlled Trial[NCT06005350] | 54 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | |||
Vitamin B3 as a Novel Mitochondrial Therapy for Obesity[NCT03951285] | 56 participants (Actual) | Interventional | 2016-05-25 | Completed | |||
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990] | Phase 2 | 5 participants (Actual) | Interventional | 2019-11-08 | Terminated (stopped due to Enrollment challenges) | ||
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity[NCT02812238] | 38 participants (Actual) | Interventional | 2016-06-23 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks
Intervention | units on a scale (Median) |
---|---|
NIAGEN®) | 7 |
Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks
Intervention | score on a scale (Median) |
---|---|
NIAGEN®) | 2 |
Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks
Intervention | event (Number) |
---|---|
NIAGEN®) | 0 |
"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks
Intervention | Participants (Count of Participants) |
---|---|
NIAGEN®) | 3 |
Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks
Intervention | Participants (Count of Participants) |
---|---|
NIAGEN®) | 0 |
Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks
Intervention | ng/ml (Median) |
---|---|
NIAGEN®) | 810 |
Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks
Intervention | mg/M^2 (Number) |
---|---|
NIAGEN®) | 200 |
The IL- 1beta secretion is measured in response to fasting, refeeding and administration of Nicotinamide Riboside (or placebo). Nicotinamide riboside acts as a fasting mimetic, and is supposed to maintain the reduction of IL-1 beta secretion (indicating NLRP3 inflammasome activation) induced by fasting. 1000 mg of Nicotinamide riboside on a daily basis is given to the subjects for a period of 7-10 days. (NCT02812238)
Timeframe: 4 weeks
Intervention | mg/dL (Mean) |
---|---|
Nicotinamide Riboside | 582 |
Placebo | 794 |
19 other studies available for niacinamide and Weight Gain
Article | Year |
---|---|
Nicotinamide Protects Against Diet-Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging.
Topics: Adipocytes, Beige; Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Anim | 2021 |
Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.
Topics: Animals; Betaine; Choline; CpG Islands; Dietary Supplements; DNA; DNA Damage; DNA Methylation; Epige | 2013 |
Pentamethylquercetin reduces fat deposition via Sirt1-mediated pathways in male obese mice induced by a high fat diet.
Topics: Adipogenesis; Adipose Tissue; Adipose Tissue, White; Animals; Diet, High-Fat; Gene Expression Regula | 2013 |
The effects of glycine, L-threonine, and L-cystine supplementation to a 9% casein diet on the conversions of L-tryptophan to nicotinamide and to serotonin in rats.
Topics: Animals; Body Weight; Caseins; Cystine; Diet; Dietary Supplements; Glycine; Male; Models, Animal; Ni | 2013 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
Effects of excess nicotinamide administration on the urinary excretion of nicotinamide N-oxide and nicotinuric acid by rats.
Topics: Animals; Dose-Response Relationship, Drug; Eating; Liver; Male; NAD; NADP; Niacinamide; Nicotinic Ac | 2004 |
The anti-hyperglycemic activity of the fruiting body of Cordyceps in diabetic rats induced by nicotinamide and streptozotocin.
Topics: Administration, Oral; Animals; Blood Glucose; Cordyceps; Diabetes Mellitus, Experimental; Diet; Dise | 2004 |
Effects of excess pantothenic acid administration on the other water-soluble vitamin metabolisms in rats.
Topics: Animals; Ascorbic Acid; Diet; Eating; Energy Metabolism; Liver; Male; Niacin; Niacinamide; Organ Siz | 2005 |
Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis.
Topics: Animals; Carboxy-Lyases; Kidney; Liver; Male; NAD; Nephrosis; Niacin; Niacinamide; Puromycin Aminonu | 2006 |
Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Do | 2006 |
GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Enzyme Activation; Glucose Transporter Type | 2007 |
Quantitative efficacy of niacin sources for chicks: nicotinic acid, nicotinamide, NAD and tryptophan.
Topics: Analysis of Variance; Animal Feed; Animals; Biological Assay; Chickens; Dose-Response Relationship, | 1993 |
Effects of vitamin B6 deficiency on the conversion ratio of tryptophan to niacin.
Topics: Animals; Diet; Feeding Behavior; Kynurenic Acid; Niacin; Niacinamide; Rats; Rats, Wistar; Tryptophan | 1995 |
Fate of nicotinamide differs due to an intake of nicotinamide.
Topics: Animals; Biotransformation; Chromatography, High Pressure Liquid; Diet; Eating; Liver; Male; Niacina | 1996 |
Increased conversion ratio of tryptophan to niacin by the administration of clofibrate, a hypolipidemic drug, to rats.
Topics: Animals; Clofibrate; Hypolipidemic Agents; Liver; Male; NAD; Niacin; Niacinamide; Rats; Rats, Wistar | 1996 |
Effects of feeding tryptophan-limiting diets on the conversion ratio of tryptophan to niacin in rats.
Topics: Amino Acids; Animals; Caseins; Diet; Eating; Gelatin; Liver; Male; Niacin; Niacinamide; Rats; Rats, | 1996 |
Tryptophan-niacin metabolism in liver cirrhosis rat caused by carbon tetrachloride.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Liver Cirrhosis, E | 1999 |
Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats.
Topics: Animals; Brain; Cerebral Infarction; Energy Metabolism; Ischemic Attack, Transient; Male; Motor Acti | 2000 |
Therapeutic window for nicotinamide following transient focal cerebral ischemia.
Topics: Animals; Behavior, Animal; Cerebral Infarction; Drug Administration Schedule; Ischemic Attack, Trans | 2002 |